Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.

Abstract titles reveal some of ASCO’s key datasets.

An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.

Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.